EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical Form Along with a New Route of Administration By Ogkologos - October 3, 2025 415 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns treatment of patients with resectable locally advanced head and neck squamous cell carcinoma Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR ESMO Highlights the Importance of Prioritising the Fight Against Cancer in... September 10, 2025 A winding journey into the world of children’s and young people’s... September 24, 2021 Prefrail and Frail Young Adult Survivors of Childhood Cancers Experience Significant... July 22, 2021 Medicare Open Enrollment Starts Tomorrow! October 14, 2021 Load more HOT NEWS Cancer in My Community: Working to Expand Access to Clinical Trials... Dexrazoxane Protects the Heart Long Term for Kids Being Treated for... Five Questions with…Fred. Mom Spots Strange Glow In Daughter’s Eye While Looking At Photo,...
